Quantcast

Groundbreaking Medication in Men’s Sexual Health to Revolutionize Treatment of Premature Ejaculation

February 10, 2012

More men suffer from premature ejaculation (PE) than any other sexual dysfunction, twice that of the more recognized erectile dysfunction. But there have been no safe and effective treatments for PE until now with the introduction of Promescent, an FDA approved, over-the-counter medication. Promescent is already being hailed as the only go-to treatment by medical experts and thought leaders worldwide.

Newport Beach, California (PRWEB) February 10, 2012

Premature Ejaculation (PE) affects approximately 30 million men in the United States, twice as many as the more highly publicized Erectile Dysfunction (ED). But unlike ED, which can be treated by effective drugs such as Viagra, Levitra and Cialis, PE is a condition that lacks a truly effective option sanctioned by the medical community and the FDA.

The frustration felt by doctors and PE sufferers, however, is now over with the introduction of Absorption Pharmaceutical´s groundbreaking treatment. Promescent is a revolutionizing, over-the-counter PE treatment approved under strict FDA monograph guidelines. CEO of AP, Jeff Abraham says, “The field of sexual medicine is dominated by behemoths like Glaxo, Pfizer, Eli Lilly and J&J so our success is all the more remarkable and a powerful testament to our breakthrough product. We remain committed to establishing Promescent as the number one preferred choice of every urologist and sexual medicine expert to treat their patients who suffer from PE.”

Dr. Ronald Gilbert, chief urologist at Hoag Hospital in Newport Beach, CA and Founder and Chief Medical Officer of Absorption Pharmaceuticals, developed the lidocaine based topical anesthetic after recognizing the absence of a safe and effective treatment for PE sufferers. “Although premature ejaculation is widely considered the most prevalent male sexual dysfunction, men who suffer from poor control of ejaculation have not had the treatment options seen in other sexual dysfunctions such as erectile dysfunction”, says Dr. Gilbert. Prior to Promescent, the most common treatment for PE was a class of daily anti-depressant medication called selective serotonin reuptake inhibitors (SSRIs). Although SSRIs address the issue of early ejaculation for some men, there are also negative side effects such as reduced sexual desire, nausea, diarrhea and insomnia. SSRIs also require a daily dosage regardless of sexual activity. Unsatisfied with SSRIs to treat PE with his own patients, Dr. Gilbert began his quest to find a better alternative.

Years of research and development by Dr. Gilbert and a major US university’s school of pharmacy resulted in Promescent, considered to be a game-changer in the treatment of PE. Unlike SSRIs, Promescent does not have the potential for side effects. The medication is sprayed on the penis and quickly absorbs to a dry state. Because of its unique patented formulation, Promescent is able to penetrate through the protective barrier of the epidermis to where the nerve endings that control ejaculation are located. This allows for the user and his partner to maintain full sexual sensation without any transference of the medication to his partner. Using a metered-dose spray bottle, Promescent can be applied in a precise, adjustable dosage. Another significant advantage to Promescent over SSRIs is its on-demand usage. Rather than the required daily intake of SSRIs, Promescent is applied 10 minutes prior to sexual activity.

Promescent has garnered overwhelming praise and acceptance by top urologists and sexual health experts worldwide as well as key opinion leaders in the field.

“Controlling ejaculation is a common request for men. I always recommend Promescent. My patients tell me that, when using Promescent, they have a significant delay in ejaculation and an improved sex life. It is easy, and it works.”

Michael Chancellor, MD, Director of Neuro-Urology, Beaumont Hospital

Pittsburg, PA

“Promescent is looking promising for my PE patients. So far, it has worked like a charm – extremely satisfied is the best way to describe its impact.”

David Cahn, MD, Foothills Urology

Lakewood, CO

“Compared to SSRIs, it is safe and effective without the unwanted side effects. Finally a great solution for those who have suffered with PE with limited treatment options.”

Stephen Hightower, MD, Coast Urology Group

Long Beach, CA

“I want people to understand how important premature ejaculation is. It is an un-met need…This is a very important product. I like it. I am going to recommend it to my patients. It´s a very, very important issue.”

Harry Fisch, MD, Weill Cornell Medical College of Cornell University

Host of “The Dr. Harry Fisch Show”

For additional media related information please contact:

May Lee/Media Consultant

Absorption Pharmaceuticals

310-367-9500

may(at)lotusmediahouse(dot)com

http://www.promescent.com


About Absorption Pharmaceuticals (AP), LLC.

Absorption Pharmaceuticals (AP), LLC., founded in 2008 and based in Newport Beach, CA, is the manufacturer of Promescent. The FDA approved treatment under strict monograph guidelines was developed by Dr. Ronald Gilbert, Urologist, Founder and Chief Medical Officer of Absorption Pharmaceuticals. The lidocaine based topical anesthetic utilizes a patented, advanced, transcutaneous absorption technology. Since Promescent´s formal introduction in 2011, it has been enthusiastically embraced by leading experts in the field of sexual medicine and practicing urologists globally. Promescent is currently sold in 42 countries and counting. AP is developing additional international distribution partnerships to continue dramatic sales growth in the coming months. The company´s mission is to be the leader in bringing awareness to the pervasive issue of premature ejaculation and providing the best, most effective treatment available. For general information or product inquires email questions to: info(at)promescent(dot)com

# # #

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/2/prweb9181910.htm


Source: prweb



comments powered by Disqus